Equities Analysts Offer Predictions for VRDN Q1 Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Viridian Therapeutics in a research note issued on Monday, January 27th. Leerink Partnrs analyst T. Smith expects that the company will earn ($0.81) per share for the quarter. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. Leerink Partnrs also issued estimates for Viridian Therapeutics’ Q2 2025 earnings at ($0.85) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($1.20) EPS, FY2025 earnings at ($3.74) EPS, FY2026 earnings at ($2.95) EPS, FY2027 earnings at ($1.36) EPS and FY2028 earnings at $1.34 EPS.

A number of other research firms also recently weighed in on VRDN. HC Wainwright reissued a “buy” rating and set a $34.00 price target on shares of Viridian Therapeutics in a research report on Monday, December 16th. TD Cowen began coverage on shares of Viridian Therapeutics in a report on Monday, November 25th. They set a “buy” rating for the company. Wells Fargo & Company restated an “equal weight” rating and issued a $27.00 target price (down previously from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. Royal Bank of Canada lifted their price target on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 17th. Finally, Needham & Company LLC restated a “buy” rating and set a $38.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, Viridian Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $35.70.

Viridian Therapeutics Price Performance

VRDN opened at $19.43 on Wednesday. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics has a twelve month low of $11.40 and a twelve month high of $27.20. The company has a fifty day simple moving average of $19.42 and a 200 day simple moving average of $19.40. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -4.51 and a beta of 1.13.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The business had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.08 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%.

Institutional Trading of Viridian Therapeutics

Several institutional investors have recently modified their holdings of VRDN. R Squared Ltd bought a new position in shares of Viridian Therapeutics in the fourth quarter valued at $26,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Viridian Therapeutics in the third quarter worth approximately $149,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Viridian Therapeutics during the third quarter valued at approximately $208,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Viridian Therapeutics by 17.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company’s stock valued at $318,000 after acquiring an additional 2,036 shares in the last quarter. Finally, AlphaCentric Advisors LLC boosted its stake in Viridian Therapeutics by 20.0% in the 3rd quarter. AlphaCentric Advisors LLC now owns 15,000 shares of the company’s stock worth $341,000 after purchasing an additional 2,500 shares during the period.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.